

Instance: composition-en-d5d0f8dae3251797998b53d83d0b35fa
InstanceOf: CompositionUvEpi
Title: "Composition for lyfnua Package Leaflet"
Description:  "Composition for lyfnua Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lyfnua"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  What is in this leaflet
1. What Lyfnua is and what it is used for
2. What you need to know before you take Lyfnua
3. How to take Lyfnua
4. Possible side effects
5. How to store Lyfnua
6. Contents of the pack and other information
         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lyfnua is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lyfnua is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lyfnua contains the active substance gefapixant.
Lyfnua is a medicine used in adults for chronic cough (cough that lasts longer than 8 weeks) and:
* the cough does not go away even after using other medicines or
* the reason for the cough is unknown.
The active substance in Lyfnua, gefapixant, blocks the action of nerves that trigger abnormal
coughing.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Lyfnua
- if you are allergic to gefapixant or any of the other ingredients of this medicine (listed in section
6).
Warnings and precautions
Talk to your doctor or pharmacist before and while taking Lyfnua if you:</p>
<ul>
<li>are allergic to medicines containing sulphonamide</li>
<li>have sleep apnoea   where your breathing stops and starts while you sleep</li>
<li>develop an acute infection of the lung / lower respiratory system (e.g., pneumonia or
bronchitis) </li>
<li>experience change in how things taste, loss of taste, or being less able to taste, that continues
even after you stop taking Lyfnua 
Children and adolescents
Do not give this medicine to children and adolescents below the age of 18 years. This is because it has
not been studied in this age group.
Other medicines and Lyfnua
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines.
Pregnancy and breast-feeding
It is not known if Lyfnua can harm your unborn baby. Therefore, it is better to avoid use of Lyfnua if
you are pregnant.
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or
pharmacist for advice before taking this medicine.
Animal studies have shown that Lyfnua may pass into breast milk. A risk for your baby cannot be
excluded. You and your doctor should decide together if you will take Lyfnua or breastfeed.
Driving and using machines
You may feel dizzy after taking Lyfnua. If this happens, do not drive or use tools or machines until
you no longer feel dizzy.
Lyfnua contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium
free .</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure.
How much to take
The recommended dose of Lyfnua is:</p>
<ul>
<li>
<p>one 45 mg tablet twice every day.
Adults with kidney problems
Your doctor may change how much and how often you take Lyfnua if:</p>
</li>
<li>
<p>you have severe kidney failure and are not on dialysis.
How to take
Swallow the tablet whole. Do not break, crush, or chew the tablet.
You can take the tablet with or without food.
If you take more Lyfnua than you should
If you take too much Lyfnua, talk to a doctor or pharmacist straight away.
If you forget to take Lyfnua
If you miss a dose, skip that dose and take the next dose at the scheduled time.
Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
</li>
</ul>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
The possible side effects are:
Very common (may affect more than 1 in 10 people)
- change in how things taste (such as a: metallic, bitter, or salty taste)
- being less able to taste
- loss of taste
Common (may affect up to 1 in 10 people)
- feeling sick (nausea)
- things tasting different than before
- cough (worsening, increase)
- dry mouth
- upper respiratory tract infection (an infection in the upper part of the airways including the nose
and throat)
- diarrhoea
- pain in your mouth or throat
- feeling less hungry than usual
- feeling dizzy
- upper abdominal (belly) pain 
- indigestion
- unusual feeling in mouth (e.g., tingling or prickling sensation)
- loss of feeling in the mouth
- increased saliva production
- insomnia (difficulty in sleeping)
Uncommon (may affect up to 1 in 100 people)
- bladder, urinary or kidney stones
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after  EXP .
The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Lyfnua contains
The active substance is gefapixant. Each film-coated tablet contains 45 mg gefapixant (as citrate).
The other ingredients are silica (colloidal anhydrous) (E551), crospovidone (E1202), hypromellose
(E464), magnesium stearate (E470b), mannitol (E421), microcrystalline cellulose (E460), sodium
stearyl fumarate. The tablets are film-coated with a coating material containing the following
ingredients: hypromellose (E464), titanium dioxide (E171), triacetin (E1518) and red ferric oxide
(E172). The tablets are polished with carnauba wax (E903).
What Lyfnua looks like and contents of the pack
Lyfnua is a pink, round and convex tablet, debossed with 777 on one side and plain on the other side.
Lyfnua is available in white PVC/PE/PVdC blisters. 
Lyfnua is available in packs containing 28, 56 and 98 film-coated tablets in non-perforated blisters
(14 tablets per card), multipacks containing 196 (2 packs of 98) film coated tables in non-perforated
blisters.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer 
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 6611 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila
d.o.o.
Tel: +386 1 5204 msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 .: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: + 371 67364msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu</p>         </div>"""      

